Imaging Brain Metabolism and Pathology in Alzheimer’s Disease with Positron Emission Tomography

@inproceedings{Shokouhi2014ImagingBM,
  title={Imaging Brain Metabolism and Pathology in Alzheimer’s Disease with Positron Emission Tomography},
  author={Sepideh Shokouhi and Daniel O. Claassen and WR Riddle},
  booktitle={Journal of Alzheimer's disease & Parkinsonism},
  year={2014}
}
Current Positron Emission Tomography (PET) biomarkers for Alzheimer's disease (AD) assess either neuronal function, or associated pathological features of this common neurodegenerative disease. The most widely accepted clinical PET tool for AD is 18-fluorodeoxyglucose PET (FDG-PET), which measures cerebral metabolic glucose utilization rate (CMRglc). FDG-PET is a marker of synaptic activity, neuronal function, and neuronal metabolic activity. AD is characterized by a distinct pattern of… CONTINUE READING